This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Abstract Details

Activity Number: 256
Type: Contributed
Date/Time: Monday, August 2, 2010 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract - #309132
Title: Comparisons of Methods in Phase I Dose-Escalation Clinical Trial Designs
Author(s): Liping Huang*+
Companies: Bayer HealthCare Pharmaceuticals
Address: 340 Changebridge Rd, Montville, NJ, 07045, USA
Keywords: Maximum Tolerated Dose ; Continual Reassessment Method ; 3+3 design ; Dose Finding ; Phase I ; clinical trial

The goal of dose-finding for phase I oncology trials is the determination of the maximum tolerated dose (MTD). The standard method to find the MTD is the so-called '3+3' design. Many new methods have been proposed which hope to estimate the true MTD more precisely than '3+3' design while using less patients. Among them, the continual reassessment method (CRM) has gained popularity since it was proposed. In this presentation, we will compare '3+3' design and its modification with CRM and its modification by simulation.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2010 program

2010 JSM Online Program Home

For information, contact or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.